Grace Therapeutics (NASDAQ:GRCE) reported quarterly earnings results on February 12, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.14, beating the consensus estimate of $-0.27 by $0.13 per share. Revenue came in at , meeting the estimate of .
Grace Therapeutics's stock moved following the earnings release. The stock currently trades at $3.50 with a market capitalization of $47.5M.


